Brain-infiltrating leukocytes contribute to
multiple sclerosis (MS) and autoimmune
encephalomyelitis and likely play a role in
traumatic brain injury, seizure, and
stroke. Brain-infiltrating leukocytes are also primary targets for MS disease-modifying
therapies. However, no method exists for noninvasively visualizing these cells in a living organism. 1-(2'-deoxy-2'-18F-fluoroarabinofuranosyl)
cytosine (18F-FAC) is a PET radiotracer that measures deoxyribonucleoside salvage and accumulates preferentially in immune cells. We hypothesized that
18F-FAC PET could noninvasively image brain-infiltrating leukocytes. Methods: Healthy mice were imaged with
18F-FAC PET to quantify if this radiotracer crosses the blood-brain barrier (BBB).
Experimental autoimmune encephalomyelitis (EAE) is a mouse disease model with brain-infiltrating leukocytes. To determine whether
18F-FAC accumulates in brain-infiltrating leukocytes, EAE mice were analyzed with
18F-FAC PET, digital autoradiography, and immunohistochemistry, and deoxyribonucleoside salvage activity in brain-infiltrating leukocytes was analyzed ex vivo.
Fingolimod-treated EAE mice were imaged with
18F-FAC PET to assess if this approach can monitor the effect of an immunomodulatory
drug on brain-infiltrating leukocytes. PET scans of individuals injected with 2-chloro-2'-deoxy-2'-18F-fluoro-9-β-d-arabinofuranosyl-adenine (18F-CFA), a PET radiotracer that measures deoxyribonucleoside salvage in humans, were analyzed to evaluate whether 18F-CFA crosses the human BBB. Results:18F-FAC accumulates in the healthy mouse brain at levels similar to
18F-FAC in the blood (2.54 ± 0.2 and 3.04 ± 0.3 percentage injected dose per gram, respectively) indicating that
18F-FAC crosses the BBB. EAE mice accumulate
18F-FAC in the brain at 180% of the levels of control mice. Brain
18F-FAC accumulation localizes to periventricular regions with significant leukocyte infiltration, and deoxyribonucleoside salvage activity is present at similar levels in brain-infiltrating T and innate immune cells. These data suggest that
18F-FAC accumulates in brain-infiltrating leukocytes in this model.
Fingolimod-treated EAE mice accumulate
18F-FAC in the brain at 37% lower levels than control-treated EAE mice, demonstrating that
18F-FAC PET can monitor therapeutic interventions in this mouse model. 18F-CFA accumulates in the human brain at 15% of blood levels (0.08 ± 0.01 and 0.54 ± 0.07 SUV, respectively), indicating that 18F-CFA does not cross the BBB in humans. Conclusion:18F-FAC PET can visualize brain-infiltrating leukocytes in a mouse MS model and can monitor the response of these cells to an immunomodulatory
drug. Translating this strategy into humans will require exploring additional radiotracers.